Pinkerton Wealth LLC Buys 1,850 Shares of Amgen Inc. $AMGN

Pinkerton Wealth LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 11.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,976 shares of the medical research company’s stock after acquiring an additional 1,850 shares during the quarter. Pinkerton Wealth LLC’s holdings in Amgen were worth $5,073,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Vanguard Group Inc. grew its holdings in shares of Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after purchasing an additional 165,281 shares during the last quarter. State Street Corp increased its position in shares of Amgen by 0.6% during the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock worth $8,196,775,000 after purchasing an additional 177,035 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Amgen by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock valued at $3,619,489,000 after purchasing an additional 291,271 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Amgen by 5.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after buying an additional 687,735 shares in the last quarter. Finally, Laurel Wealth Advisors LLC boosted its position in Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after buying an additional 6,676,575 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

AMGN has been the subject of several recent analyst reports. Guggenheim raised their price objective on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Deutsche Bank Aktiengesellschaft boosted their target price on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. UBS Group increased their price target on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Morgan Stanley raised their price target on Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. Finally, Cantor Fitzgerald lifted their price objective on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $354.17.

Amgen Trading Up 2.0%

Shares of NASDAQ AMGN opened at $376.97 on Tuesday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a 50-day moving average of $354.21 and a two-hundred day moving average of $323.38. The company has a market cap of $203.21 billion, a PE ratio of 26.49, a P/E/G ratio of 3.67 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.